Largent Health

Largent Health is a clinical-stage biotechnology company focused on the development of novel therapies for rare metabolic and genetic bone diseases. The company's primary focus is the advancement of its lead candidate, LGT-101, which is a recombinant human alkaline phosphatase. LGT-101 is being developed as an enzyme replacement therapy for patients suffering from hypophosphatasia (HPP), a serious and potentially life-threatening genetic disorder. Founded by a team of seasoned rare disease executives and backed by Deerfield Management, the company operates out of New York City. Largent Health leverages its leadership's extensive experience in the orphan drug space to accelerate the delivery of transformative treatments to patients with high unmet needs.